Enrollment paused in some Kite/NCI trials

Kite Pharma Inc. (NASDAQ:KITE) said enrollment of patients is paused in clinical studies conducted jointly with NCI while NIH conducts a "voluntary internal review" of all NCI facilities involved with sterile material. Kite said patients already enrolled in the studies will continue to receive treatment.

Kite said the review is not related to its own manufacturing facilities, and said its four ongoing, pivotal Phase I/II and Phase II trials of lead compound KTE-C19 to treat hematological malignancies are not affected. The product is a chimeric antigen receptor (CAR) T cell therapy against CD19. ...